New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
10:04 EDTSYK, TRNX, JNJ, IART, ZMH, SNN, WMGIVolume trends from CCJR meeting positive for Zimmer, says Piper Jaffray
Piper Jaffray said it has more confidence in improving volume trends in the orthopedic market following its attendance at the Current Concepts in Joint Replacement meeting, which it views as particularly positive for Zimmer (ZMH). The firm also said the trends and expectations pointed to at the meeting were positive, but to a lesser extent, for Tornier (TRNX), Wright Medical (WMGI), Integra LifeSciences (IART), Stryker (SYK), Smith & Nephew (SNN) and Johnson & Johnson (JNJ).
News For ZMH;TRNX;WMGI;IART;SYK;SNN;JNJ From The Last 14 Days
Check below for free stories on ZMH;TRNX;WMGI;IART;SYK;SNN;JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
15:00 EDTWMGI, JNJWright Medical hip suit weakness would be buying opportunity, says Brean Capital
Subscribe for More Information
10:02 EDTSNNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:30 EDTIARTIntegra LifeSciences announces changes within Orthopedics, Tissue Technologies
Subscribe for More Information
05:22 EDTSNNSmith & Nephew downgraded to Hold from Buy at Jefferies
September 1, 2014
20:40 EDTTRNXTornier management to meet with JPMorgan
Subscribe for More Information
August 31, 2014
14:04 EDTJNJWorldwide Business Research to hold a conference
Subscribe for More Information
13:59 EDTWMGIRW Baird to hold a conference
Subscribe for More Information
13:23 EDTSNNGoldman to hold a conference
Subscribe for More Information
August 28, 2014
17:42 EDTJNJJ&J begins sales process for its medical device unit Cordis, WSJ says
Subscribe for More Information
August 25, 2014
08:27 EDTJNJJanssen Affiliate Cilag acquires Covagen, terms not disclosed
Subscribe for More Information
07:03 EDTJNJVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.
August 24, 2014
21:54 EDTIARTPiper Jaffray to hold a bus tour
Subscribe for More Information
August 21, 2014
05:42 EDTJNJIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use